Linagliptin Sandoz

Linagliptin, the active ingredient in Linagliptin Sandoz, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when combined with diet and exercise.

GNH USA supplies Linagliptin Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Linagliptin is a DPP-4 inhibitor used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder.

- Type 2 diabetes mellitus: improves blood glucose levels by enhancing insulin secretion and reducing glucagon release. - Adjunct to diet and exercise: used when lifestyle modifications alone do not achieve target glycaemic control. - Combination therapy: can be added to metformin, sulfonylureas or insulin to further lower HbA1c.

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Upper respiratory tract infection - Nasopharyngitis - Headache - Dizziness

Serious or Rare Side Effects: - Pancreatitis - Severe hypersensitivity reactions (e.g., angioedema, anaphylaxis) - Hypoglycaemia when combined with insulin or sulfonylureas - Rare worsening of renal impairment

When prescribing Linagliptin, clinicians should consider several safety and handling points.

- Renal function: dose adjustment is not required, but monitor patients with severe renal impairment. - Hepatic impairment: use with caution in patients with moderate hepatic disease. - Hypoglycaemia risk: increased when used with insulin or sulfonylureas; monitor glucose levels. - Pancreatitis: discontinue if signs of pancreatitis appear. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Linagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycaemia; dose adjustment required. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Rifampin (strong inducer): may reduce linagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides): may affect glucose control. - Beta‑blockers: may mask hypoglycaemia symptoms. - Warfarin: monitor INR as occasional interaction reported.